(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
23 September 2021 (23.09.2021)

WIPO | PCT

(10) International Publication Number
WO 2021/188688 A1

(51) International Patent Classification:
A61K 31/422 (2006.01) *A61K 31/428* (2006.01)
A61K 31/4245 (2006.01)

(21) International Application Number:
PCT/US2021/022786

(22) International Filing Date:
17 March 2021 (17.03.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

62/991,292	18 March 2020 (18.03.2020)	US
63/069,667	24 August 2020 (24.08.2020)	US
63/140,735	22 January 2021 (22.01.2021)	US

(71) Applicant: **METACRINE, INC.** [US/US]; 3985 Sorrento Valley Blvd., Suite C, San Diego, California 92121 (US).

(72) Inventors: **SONG, Kenneth**; 3985 Sorrento Valley Blvd., Suite C, San Diego, California 92121 (US). **CHEN, Hubert**; 3985 Sorrento Valley Blvd., Suite C, San Diego, California 92121 (US). **WAGNER, Brandee**; 3985 Sorrento Valley Blvd., Suite C, San Diego, California 92121 (US). **SMITH, Nicholas D.**; 3985 Sorrento Valley Blvd., Suite C, San Diego, California 92121 (US).


(74) Agent: **ZUNIC, Valentin B.** et al.; WILSON SONSINI GOODRICH & ROSATI, 650 Page Mill Road, Palo Alto, California 94304 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,

(54) Title: FARNESOID X RECEPTOR AGONISTS FOR THE TREATMENT OF DISEASE

FIG. 1



(57) Abstract: Described herein is the use of farnesoid X receptor (FXR) agonists, alone or in combination with additional therapies, in the treatment or prevention of diseases, conditions, or disorders that would benefit from therapy with a FXR agonist.

WO 2021/188688 A1

[Continued on next page]

MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

— *with international search report (Art. 21(3))*